Today, we reported Q1 2024 financial results and a business update. This includes the news of our nomination of development candidate APG990, with a Phase 1 clinical trial in healthy volunteers expected to initiate ahead of schedule in 2H 2024. Additionally, we announced the initiation of a Phase 2 clinical trial of APG777 in patients with moderate-to-severe #atopicdermatitis (AD), with 16-week proof-of-concept data expected in 2H 2025. With $816M in total cash following our recent upsized follow-on offering, we now have projected cash runway into 2028. Full details here. https://lnkd.in/gCeNjuCr
Best of luck!
Fantastic news, Apogee Therapeutics!!
Well done!
Keep growing!
Way to go T.!
Professional Job Whisperer - Senior Consultant, Life Sciences
2moMaking amazing strides here, Apogee Therapeutics. Congrats!